SecBot SecBot

TAK drug pipeline

$21.59
+0.8% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.4%
1-day, median of 19 events
IV rank
No data
No current options data
Rated drugs
14
1 bullish · 2 mixed · 11 neutral
Phase 3 trials
22
11 with results posted

Upcoming catalysts

2 dated
  1. Feb 5, 2027
    Zasocitinib (Dose A)
    Phase 2 primary completion
  2. Feb 10, 2027
    GATTEX/REVESTIVE
    Phase 3 primary completion

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 3 (registrational, completed positively)
Time to marketChina NDA is under priority review (filed June 2026); decision could come in 2026-2027. Takeda plans to seek Japan approval in 2027. US and EU regulatory filings are further out, pending additional global Phase 3 data.

arcotatug tavatecan Updated Oct 29

What to watch

The positive Phase 3 readout is already out, so the next catalysts to watch are: (1) NMPA priority-review decision in China (Innovent's NDA, filed June 2026) and (2) Takeda's planned Japan regulatory filing, expected around 2027. Neither date is fixed yet. Takeda is also initiating global Phase 3 trials in gastric and pancreatic cancer. The FDA Fast Track designation in pancreatic cancer opens another potential value driver, but it is early stage.

Bull case
  • Phase 3 G-HOPE-001 met both primary endpoints with strong statistical significance: median OS of 10.2 vs 6.9 months (HR=0.57, p<0.0001) and median PFS of 5.5 vs 2.9 months (HR=0.47) in heavily pretreated patients.
  • The drug has a differentiated mechanism as a CLDN18.2-targeted ADC with Fc silencing designed to reduce off-target toxicity, potentially giving it a better safety profile than competitor ADCs.
  • First CLDN18.2 ADC to submit for regulatory review anywhere; NDA accepted with priority review by China's NMPA in June 2026.
Bear case
  • Takeda's $1.2 billion upfront payment plus up to $10.2 billion in milestones for this and other Innovent assets is a large financial commitment with uncertain commercial returns.
  • Zolbetuximab (Vyloy, Astellas) is already approved as a first-line CLDN18.2 therapy, and other CLDN18.2 ADCs like sonesitatug vedotin also showed Phase 3 success at ESMO 2026, creating a crowded competitive field.
  • arcotatug tavatecan is currently only studied in later-line treatment (third-line or later); earlier lines and pancreatic cancer remain unproven.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2014 (IV) and recently launched subcutaneously (Entyvio Pen). Biosimilar entry is the main future risk, with Alvotech's AVT16 BLA accepted for FDA review as of June 2026 and AVT80 BLA accepted in August 2026.

ENTYVIO vedolizumab Updated Oct 29

What to watch

With the VERDICT Phase 4 data already released (October 19, 2026) and no upcoming FDA decision or pivotal readout for ENTYVIO itself, the next catalysts for TAK shareholders are the biosimilar patent litigation outcomes against Alvotech, Polpharma, and Samsung, plus quarterly sales trends. Litigation timelines are uncertain, making the near-term binary low for this specific drug.

Bull case
  • Positive Phase 4 VERDICT data (October 19, 2026) showed that treating UC patients to achieve disease clearance with ENTYVIO reduced the risk of disease-related complications by approximately 67% (HR 0.33) compared to targeting symptomatic remission alone, which could strengthen the drug's clinical positioning and potentially expand utilization.
  • Entyvio remains a multi-billion-dollar blockbuster and key growth driver for Takeda. The company raised its FY2026 revenue guidance to JPY 4,700 billion (from JPY 4,640 billion) on October 29, 2026, partly reflecting strong performance from its Growth & Launch Products including ENTYVIO.
  • Institutional accumulation: Major funds including FMR LLC (Fidelity) added 34.9% to their TAK position in Q2 2026, and Qube Research & Technologies opened a new ~$35M position, while the analyst consensus shows 14 buy/strong-buy ratings vs 7 holds and zero sells.
Bear case
  • Multiple biosimilar threats: Alvotech's AVT16 (IV) and AVT80 (SC) biosimilar BLAs were accepted for FDA review in 2026, and Alvotech reported positive Phase 1 PK data for AVT80 in February 2026. Takeda has filed BPCIA patent lawsuits against Alvotech (September 2026), Polpharma Biologics (August 2026), and Samsung is also challenging Entyvio IP, but the patent thicket can only delay, not prevent, biosimilar entry.
  • Insider selling: Takeda executives including CEO Julie Kim, R&D President Andrew Plump, and several other officers sold shares in August-September 2026 at prices around $17-18.50, with the CEO selling ~$1.5M worth on August 10, 2026.
  • Competitive pressure from newer oral therapies (JAK inhibitors like Rinvoq, S1P receptor modulators, and Gilead's emerging emvistegrast) could erode Entyvio's positioning in the IBD market over time.
▲ bullish
Impact
PhaseApproved
Time to marketAlready approved in the US (August 28, 2026) and commercially available. EU status is orphan designation only with no marketing authorization yet; no regulatory submission date has been announced for Europe or other regions.

MIMRYLO rusfertide Updated Oct 29

What to watch

MIMRYLO's commercial launch is the current focus. Watch Takeda's Capital Markets Day on December 11, 2026 for sales trajectory updates and progress toward the $1-2B peak sales target. The key variable is whether MIMRYLO can capture share from established competitors Jakafi (ruxolitinib) and Besremi (ropeginterferon alfa-2b). Any EU regulatory submission would be the next hard catalyst, but no filing date has been announced yet.

Bull case
  • First-in-class hepcidin mimetic with novel mechanism of action distinct from existing PV treatments (Jakafi, Besremi)
  • Pivotal Phase 3 VERIFY trial showed 76.9% clinical response rate vs 32.9% placebo, meeting all efficacy endpoints
  • NCCN Category 1 recommendation across both low- and high-risk PV, the only drug to hold that distinction
Bear case
  • Already approved, so no binary approval catalyst remains for share price appreciation
  • Competes against established therapies Incyte/Novartis' Jakafi (ruxolitinib) and PharmaEssentia's Besremi (ropeginterferon alfa-2b)
  • Requires weekly subcutaneous injection, which may be a barrier for some patients vs oral Jakafi
● neutral
Impact
PhaseApproved
Time to marketApproved but awaiting DEA scheduling before US dispensing (expected by November 2026); already launched in Japan and China (October 2026).

ORZEYFUL oveporexton Updated Oct 29

What to watch

Watch for the DEA scheduling decision expected by November 2026, which will determine when Orzeyful can be dispensed in the US. Also watch Takeda's December 11, 2026 Capital Markets Day for peak-sales targets and Q3 brand growth. The stock is down ~1.9% today at $19.77 as of this report.

Bull case
  • First-in-class oral orexin receptor 2 (OX2R) agonist, the first drug to treat the underlying orexin deficiency causing narcolepsy type 1 rather than just symptoms.
  • Met all primary and secondary endpoints in two pivotal Phase 3 trials (FirstLight and RadiantLight), showing statistically significant improvements in wakefulness and daily functioning.
  • Approved in the US (August 5, 2026), China (July 2026), and Japan (October 2026), with launches underway in Japan and China.
Bear case
  • DEA scheduling still pending; the FDA approval letter states scheduling under the Controlled Substances Act is not yet complete, and Orzeyful cannot be dispensed until the DEA publishes a scheduling notice, expected by November 2026.
  • Label is limited to narcolepsy type 1 (NT1) in adults only, excluding the larger narcolepsy type 2 population and children, limiting the addressable market.
  • Takeda is a large diversified pharma; Orzeyful is a small part of a broad portfolio, so even blockbuster sales would have modest impact on the overall stock.
● neutral
Impact
PhaseApproved and marketed
Time to marketAlready marketed. Launched in Japan in February 2015. US launch via Phathom as Voquezna in late 2023. Korean launch with insurance coverage begins November 1, 2026.

TAKECAB/VOCINTI vonoprazan Updated Oct 29

What to watch

The next near-term event for the drug is the Korean national insurance reimbursement launch on November 1, 2026, announced today. This is a commercial expansion into a competitive market already dominated by three Korean-developed P-CABs (K-CAB, Fexuclue, Jaqbo). For a diversified pharma like Takeda, the stock move from vonoprazan-specific news is likely to be small; watch Phathom Pharmaceuticals (PHAT) for US Voquezna sales trajectory and the Phase 2 EoE readout expected late 2026/early 2027 instead.

Bull case
  • Vonoprazan is a first-in-class P-CAB, the first major innovation in acid-reducing therapy in over 30 years, offering rapid and sustained acid suppression compared to standard PPIs.
  • Takeda's TAKECAB/VOCINTI franchise revenue grew 9.9% in FY2025 to JPY 143.7 billion (~$950M), driven by strong demand in Japan and China.
  • Korean national insurance reimbursement starting November 1, 2026 opens a new market; Korea's P-CAB market is expected to exceed 400 billion won (~$285M) in 2026.
Bear case
  • Intense competition in Korea from three established locally-developed P-CABs (K-CAB, Fexuclue, Jaqbo) with K-CAB alone posting ~$570M in prescriptions since 2019, making it hard for late-entrant Vocinti to gain significant share.
  • Takeda's compound patent for vonoprazan nears expiration in 2027 in key markets, and over 20 Korean generic manufacturers are preparing to enter the P-CAB space.
  • Vonoprazan contributes roughly 3% of Takeda's total revenue (JPY 143.7B out of ¥4.51T), so even strong sales growth has limited impact on the overall Takeda stock.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market since 2015 (US) and 2018 (EU). The latest expanded indication was approved in September 2025 (US) and July 2026 (EU pediatric).

VONVENDI vonicog alfa Updated Oct 29

What to watch

With VONVENDI's expanded FDA approval already secured (September 2025) and no pending PDUFA or pivotal readout on the horizon, the stock-moving catalyst for Takeda related to this drug has passed. Watch Takeda's quarterly earnings (next: H1 FY2026, reported October 29, 2026) for VONVENDI sales growth as a signal of commercial execution under the expanded label, but this single product is too small to drive Takeda's share price directionally.

Bull case
  • VONVENDI is the only recombinant (non-plasma-derived) von Willebrand factor therapy approved in the US, avoiding the theoretical pathogen risk associated with human plasma-derived products. The September 2025 FDA expansion dramatically broadened the addressable population to all adult VWD types (1, 2 and 3) plus pediatric patients, representing a major market expansion. Sales grew 32.5% YoY to JPY 16.2 billion in FY2025, driven by expanded indications and increased US demand. The EU counterpart Veyvondi received pediatric approval in 2026, opening another growth avenue. Takeda holds orphan drug exclusivity, and the VWD treatment market is projected to reach ~$1 billion by 2032-2035.
Bear case
  • VONVENDI is a tiny product within Takeda's massive portfolio (~JPY 16B of JPY ~4.5T total revenue, roughly 0.4%), so even strong sales growth has negligible impact on Takeda's stock. The VWD therapeutic market is relatively small (~$580 million in 2025), limiting peak revenue potential. VONVENDI faces entrenched competition from established plasma-derived products (CSL Behring's Humate-P, Octapharma's Wilate), which have decades of clinical data and physician familiarity. There are no upcoming binary catalysts (PDUFA dates, pivotal readouts) for this drug, making it a slow commercial story with no event-driven upside for the stock. Competitors are also expanding into pediatrics, narrowing VONVENDI's differentiation.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market; initial FDA approval was in 2011, with multiple label expansions since. No new market entry is pending.

ADCETRIS brentuximab vedotin Updated Oct 29

What to watch

ADCETRIS is a mature commercial asset with no hard binary catalyst on the near-term calendar. Investors should watch for any new Phase 3 data readouts for label expansion (such as the ongoing S1826 trial comparing it against nivolumab combinations), biosimilar entry timelines as patents begin expiring, and quarterly revenue trends within Takeda's oncology segment reports.

Bull case
  • Multiple approved indications across CD30-positive lymphomas provide a broad and durable revenue base
  • Recent EU approval of the BrECADD regimen (June 2025) expands the frontline Hodgkin lymphoma market for Takeda's territory
  • ADCETRIS is part of the growing ADC drug class and has established real-world clinical data and reimbursement across Takeda's markets
Bear case
  • US patents for ADCETRIS began expiring in 2024, opening the door to biosimilar competition and eventual revenue erosion
  • ADCETRIS faces competition from newer, potentially more effective therapies including PD-1 inhibitors like Keytruda (pembrolizumab) and other ADCs
  • Takeda only controls ex-US/Canada rights, limiting upside compared to a global owner
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed in the U.S. (November 2023) and EU (August 2024). Label expansion for iTTP is in Phase 2b testing with no near-term regulatory filing expected.

ADZYNMA apadamtase alfa Updated Oct 29

What to watch

ADZYNMA does not drive the investment case for TAK on its own. The next relevant catalyst is Takeda's Capital Markets Day on December 11, 2026, where corporate strategy and pipeline updates across the entire portfolio will be discussed. For ADZYNMA specifically, watch for Phase 2b iTTP data and any postmarketing immunogenicity study results, but neither is a near-term binary for the stock.

Bull case
  • ADZYNMA is the first and only FDA-approved recombinant ADAMTS13 therapy for cTTP, a condition with ~90% mortality when untreated, giving it a strong orphan-drug moat with orphan exclusivity until 2030+ in both the US and EU.
  • The drug also carries a Rare Pediatric Disease Voucher (already granted to Takeda), which has standalone value.
  • ADZYNMA is a small but growing contributor to Takeda's Growth & Launch Products category alongside larger assets like ENTYVIO and TAKHZYRO, and label expansion into iTTP (a larger addressable market) is under investigation in Phase 2b.
Bear case
  • The FDA mandated a Boxed Warning (September 2026) after postmarketing reports of neutralizing antibodies that can block ADZYNMA's effect, including the death of a 7-year-old child. This is the most serious FDA warning and could materially dampen physician and patient adoption.
  • cTTP is an ultra-rare disease with a very small patient population, capping peak sales potential. ADZYNMA is a minor asset within Takeda's massive portfolio and will not move the stock meaningfully on its own.
  • The label is currently limited to cTTP. The iTTP opportunity is still early-stage (Phase 2b), faces competition from Sanofi's already-approved Cablivi (caplacizumab), and carries no guarantee of success.
◆ mixed
Impact
PhaseApproved (marketed)
Time to marketAlready approved and commercially available since 2012 (US/EU).

GATTEX/REVESTIVE teduglutide Updated Oct 29

What to watch

With all US Orange Book patents and FDA exclusivity expired (May 2026), watch for generic teduglutide entrants that could erode Gattex/Revestive's roughly JPY 145 billion revenue base. Separately, Ironwood's once-weekly apraglutide has positive Phase 3 STARS data published in October 2026, while Lilly's $1.26B sonefpeglutide deal adds another long-acting competitor. Takeda's next quarterly update (likely January 2027) will show whether Gattex/Revestive revenue held or declined following the exclusivity loss.

Bull case
  • Teduglutide is the only approved pharmacotherapy for short bowel syndrome (SBS), a rare, life-altering condition with few alternatives, supporting durable orphan-drug pricing power.
  • The label now covers both adults and pediatric patients 1 year and older, expanding the addressable population, and Takeda's long-term safety registry continues to build real-world evidence.
  • Takeda guided FY2026 Gattex/Revestive revenue to 154 billion yen (roughly $1 billion), up 6% reported from FY2025, and first-half FY2026 results (published Oct 29, 2026) reiterated that outlook.
Bear case
  • Exclusivity has expired: all FDA Orange Book patents and regulatory exclusivity for Gattex Kit lapsed by May 16, 2026, opening the door for generic teduglutide entrants that could dramatically cut Takeda's roughly JP 145.7 billion in annual revenue.
  • Competing once-weekly GLP-2 analogs threaten the daily-injection profile of teduglutide. Ironwood's apraglutide posted positive Phase 3 STARS results in October 2026, and Lilly paid up to $1.26 billion for Hanmi's long-acting GLP-2 sonefpeglutide (Phase 2).
  • Revenue is largely flat: Gattex/Revestive grew only 1% at constant exchange rates in FY2025, and Takeda's own FY2026 guidance of 154 billion yen implies just 1% CER growth.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 1985. All major depot formulations (1-month, 3-month, 6-month) are on the market globally.

LEUPLINENANTONE leuprorelin acetate Updated Oct 29

What to watch

Leuprorelin acetate is a mature, off-patent product for Takeda. Watch for generic erosion in Takeda's Japan and EU revenue disclosures during quarterly earnings, but there is no single binary catalyst for this drug that would move TAK shares. Takeda's next major pipeline catalysts include the Phase 3 readout for zasocitinib and the ongoing commercial launch of ORZEYFUL (oveporexton) and MIMRYLO (rusfertide), which are far more material to the stock.

Bull case
  • Leuprorelin acetate remains a standard of care for prostate cancer and other hormone-dependent conditions globally, with the leuprolide acetate market valued at around $2.9-3.1 billion in 2026 and projected to grow at 4.7-6.4% CAGR through 2030.
  • Takeda's established manufacturing and distribution infrastructure for leuprorelin depot formulations in Japan and Europe provides a steady revenue stream. Takeda is one of the few manufacturers of this complex injectable depot product.
  • Takeda's overall business showed strong H1 FY2026 results (reported Oct 29, 2026) with revenue up 8.4% AER and net profit up 171.8%, driven in part by the broad product portfolio.
Bear case
  • Generic competition is eroding revenue: leuprolide acetate is off-patent, with multiple generic entrants in major markets including a generic injection launched by Avenacy in 2025. The leuprorelin drugs market faces pricing pressure.
  • Takeda's leuprorelin products are mature (first approved in 1985) and face declining sales as newer hormone therapies (GnRH antagonists like relugolix, oral therapies) gain share.
  • Insider selling at Takeda has been heavy in the past 90 days, with 10+ executives selling shares in August-September 2026, including the CEO and President of R&D.
● neutral
Impact
PhaseApproved
Time to marketAlready marketed (FDA-approved November 2021)

LIVTENCITY maribavir Updated Oct 29

What to watch

Watch for updates in Takeda's patent litigation against Qilu Pharmaceutical (ANDA filed 2026) which could affect LIVTENCITY's generic timeline; also monitor quarterly sales growth rate and any label expansion progress for first-line CMV treatment. The drug's next material catalyst would be a successful front-line indication trial, but none is currently on a near-term regulatory calendar.

Bull case
  • First and only FDA-approved drug specifically for post-transplant CMV infection/disease that is refractory to conventional antivirals, addressing a significant unmet medical need (source: fda.gov)
  • Q1 FY2026 sales of JPY 14.1 billion (roughly $93M) grew 20.8% at constant currency, driven by strong US performance; annualized run rate around JPY 56B ($370M) (source: investing.com)
  • Approved in 30+ countries including Japan (June 2024), providing geographic expansion upside (source: takeda.com/newsroom)
Bear case
  • NCE (new chemical entity) exclusivity expired November 2025, opening the door for generic ANDA filers; Qilu Pharmaceutical filed for generic maribavir in 2026, triggering patent litigation from Takeda (source: bloomberglaw.com)
  • The Phase 3 AURORA trial evaluating maribavir as a first-line treatment for CMV in hematopoietic stem cell transplant recipients missed its primary endpoint in 2022, limiting label expansion prospects (source: takeda.com/newsroom)
  • LIVTENCITY represents only ~1.25% of Takeda's ¥4.5 trillion ($28B) annual revenue, so swings in this drug's sales have minimal stock impact for the parent company
◆ mixed
Impact
PhaseApproved
Time to marketAlready approved and marketed since November 2015.

NINLARO ixazomib Updated Oct 29

What to watch

No hard, dated catalyst exists for NINLARO over the next 12 months. Watch for any Takeda disclosure of NINLARO-specific sales trends in quarterly earnings (next expected around late January 2027 for Q3 FY2026) and for potential label changes or post-marketing study requirements stemming from the critical meta-analyses. NINLARO's commercial trajectory as a mature product will be gradual, not binary; near-term share moves for TAK will be driven by broader portfolio events (ENTYVIO, TAKHZYRO, new launches) rather than this one drug.

Bull case
  • First and only oral proteasome inhibitor, offering convenience vs. injectable competitors (bortezomib, carfilzomib) and potentially improving patient adherence.
  • Global ixazomib market was valued at approximately $1.8 billion in 2025 and projected to grow at a ~7-8% CAGR through 2034, driven by rising multiple myeloma incidence and preference for oral regimens.
  • Already an approved, revenue-generating product with an established commercial footprint in a large and growing multiple myeloma treatment market.
Bear case
  • A 2025 systematic review and meta-analysis from ASH found ixazomib has failed primary endpoints in numerous trials and demonstrated worse survival in the maintenance setting (TOURMALINE-MM3/MM4), raising questions about its clinical value.
  • Final overall survival analyses from TOURMALINE-MM3 and MM4 (published 2025) showed no statistically significant survival improvement over placebo.
  • Intense competition from established injectable proteasome inhibitors (bortezomib generics, carfilzomib) and newer, more potent modalities like CAR-T therapies (idecabtagene vicleucel, ciltacabtagene autoleucel).
● neutral
Impact
PhasePhase 3
Time to marketTakeda plans to submit marketing applications to the FDA, EMA and Japan's PMDA during its fiscal year 2026, which ends March 31, 2027. If submissions occur by that date, potential US approval would likely come 10-12 months later, putting a possible launch in late 2027 or 2028.

TAK-881 immune globulin subcutaneous (human), 20% solution with recombinant human hyaluronidase Updated Oct 29

What to watch

Watch for Takeda's regulatory submissions for TAK-881 in the US, EU and Japan, expected by the end of its fiscal year (March 31, 2027). A submitted BLA would trigger a 10-12 month FDA review cycle and set a PDUFA date, creating a future binary catalyst. Also monitor the Phase 3 CIDP study (TAK-881-3003, MIgGRATE) for potential label expansion. For a company of Takeda's size, none of these events alone will dramatically move the stock.

Bull case
  • Phase 2/3 data showed strong PK comparability to HYQVIA with a geometric mean ratio of 99.67%, meeting the primary endpoint cleanly.
  • TAK-881 cuts infusion volume by 50% and median one-site infusion time from 132 to 75.8 minutes (a 42.6% reduction), a meaningful patient convenience improvement that could drive market share gains over HYQVIA.
  • The global immunoglobulin market is large (estimated $22-24 billion in 2025-2026) and growing at a mid-single to low-double-digit CAGR, providing a sizable addressable market for an improved product.
Bear case
  • TAK-881 is a line extension/upgrade of HYQVIA (a product Takeda already sells), so much of the revenue may be cannibalistic rather than additive to Takeda's overall IG franchise.
  • No regulatory submissions have been filed yet. The fiscal 2026 timeline (by March 31, 2027) is a target, not a commitment, and any delay pushes approval further out.
  • Takeda is a massive, diversified global pharma ($30B+ revenue) with dozens of pipeline programs. TAK-881's success or failure will have a very modest impact on the overall stock price.
● neutral
Impact
PhaseApproved
Time to marketAlready marketed since 2013. The key commercial change is the expected loss of exclusivity in December 2026, allowing generic competition.

TRINTELLIX vortioxetine hydrobromide Updated Oct 29

What to watch

No upcoming regulatory decision or clinical readout is scheduled for TRINTELLIX; the next material event is the expected arrival of generic vortioxetine in pharmacies around December 2026, which the market and Takeda have already anticipated. For Takeda investors, watch the company's broader pipeline (e.g., newer launches replacing TRINTELLIX revenue) and debt reduction progress rather than this single product.

Bull case
  • TRINTELLIX is an established brand with over a decade of market presence, generating approximately JPY 121.8 billion in annual revenue for Takeda (FY2025, ended March 2026).
  • Takeda has already taken steps to manage the transition, including assuming full US control from Lundbeck (effective January 2025) and restructuring its neuroscience field force. The company is creating 400+ new launch roles for other pipeline products.
  • The drug's multimodal mechanism gives it a differentiated profile versus traditional SSRIs/SNRIs, supporting physician adoption and formulary positioning.
Bear case
  • Generic competition is expected to begin in December 2026 (roughly two months away), which will significantly erode TRINTELLIX revenue and market share in the US.
  • Takeda has already cut 243 US neuroscience field roles (including ~190 sales positions) in preparation for the patent loss, signaling expected revenue decline.
  • The drug failed to show statistically significant superiority over placebo in pediatric clinical trials, limiting label expansion potential.

Other drugs in filings and trials

no drug report yet
  • EOHILIA Last: Approval · Feb 9, 2024
  • FRUZAQLA Last: Approval · Nov 8, 2023
  • EXKIVITY Last: Approval · Sep 15, 2021
  • MOTEGRITY Last: Approval · Dec 14, 2018
  • MYDAYIS Last: Approval · Jun 20, 2017
  • ALUNBRIG Last: Approval · Apr 28, 2017
  • VYVANSE Last: Approval · Jan 28, 2017
  • DEXILANT SOLUTAB Last: Approval · Jan 26, 2016
  • FOSRENOL Last: Approval · Sep 24, 2014
  • OSENI Last: Approval · Jan 25, 2013
  • GATTEX KIT Last: Approval · Dec 21, 2012
  • ICLUSIG Last: Approval · Dec 14, 2012
  • OMONTYS Last: Approval · Mar 27, 2012
  • Adenuric 1 trial
  • Budesonide 1 trial
  • Dexlansoprazole 2 trials
  • HGT-1110 1 trial
  • Lanthanum Carbonate 1 trial
  • Pioglitazone 1 trial
  • Soticlestat 3 trials
  • TAK-101 1 trial
  • TAK-186 1 trial
  • TAK-279 2 trials
  • TAK-280 1 trial
  • TAK-341 1 trial
  • TAK-771 2 trials
  • TAK-788 1 trial
  • Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) 1 trial
  • TDV 1 trial
  • Tetravalent Dengue Vaccine (TDV) 1 trial
  • Zasocitinib (Dose A) 1 trial

Past FDA events & how the stock moved

19 events
DateDrugEvent1 day5 days
Apr 18, 2024ENTYVIOApproval+0.7%−0.6%
Feb 9, 2024EOHILIAApproval+2.2%+4.4%
Nov 8, 2023FRUZAQLAApproval−1.4%−0.7%
Sep 27, 2023ENTYVIOApproval−2.3%−8.3%
Nov 23, 2021LIVTENCITYApproval−1.2%−4.6%
Sep 15, 2021EXKIVITYApproval+2.7%+1.5%
Dec 14, 2018MOTEGRITYApproval−5.4%−4.9%
Jun 20, 2017MYDAYISApproval0.0%+0.9%
Apr 28, 2017ALUNBRIGApproval+0.3%+1.0%
Jan 28, 2017VYVANSEApproval+0.5%+4.9%
Jan 26, 2016DEXILANT SOLUTABApproval+1.6%+3.5%
Nov 20, 2015NINLAROApproval+1.6%−2.4%
Sep 24, 2014FOSRENOLApproval−1.6%−4.0%
May 20, 2014ENTYVIOApproval−0.1%+1.9%
Sep 30, 2013TRINTELLIXApproval−0.3%−1.3%
Jan 25, 2013OSENIApproval+1.8%+1.6%
Dec 21, 2012GATTEX KITApproval−0.4%−3.3%
Dec 14, 2012ICLUSIGApproval+0.9%+1.2%
Mar 27, 2012OMONTYSApproval−4.2%−6.9%

Clinical trials

40 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
GATTEX/REVESTIVEA Study of Teduglutide in Chinese Adults With Short Bowel SyndromePhase 3Active not recruiting13Feb 10, 2027
Zasocitinib (Dose A)A Study of Zasocitinib in Adults With Hidradenitis SuppurativaPhase 2Active not recruiting91Feb 5, 2027
TAK-788A Study of TAK-788 in Adults With Non-Small Cell Lung CancerPhase 2Completed324Sep 29, 2026
TAK-788TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsPhase 3Completed354Sep 22, 2026
Tetravalent Dengue Vaccine (TDV)A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy AdultsPhase 3Active not recruiting496Aug 30, 2026
AdenuricImmediate Prescription of a Hypouricemic Treatment, Febuxostat, Compared to Its Delayed AdministrationPhase 3Completed9Aug 10, 2026
LIVTENCITYA Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) InfectionsPhase 3Completed20Jul 22, 2026
DexlansoprazoleA Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years OldPhase 2Completed71Jul 21, 2026
BrigatinibAdvancing Brigatinib Properties in ALK+ NSCLC Patients by Deep PhenotypingPhase 2Completed118May 30, 2026
TAK-279A Study of TAK-279 in Participants With Moderate-to-Severe Plaque PsoriasisPhase 3Active not recruiting1,950May 7, 2026
ZasocitinibA Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque PsoriasisPhase 3Completed606Apr 22, 2026
PonatinibA Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic LeukemiaPhase 2Terminated4Apr 21, 2026
VONVENDIA Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)Phase 3Completed47Apr 17, 2026
ADZYNMAA Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)Phase 2Completed29Apr 16, 2026
DexlansoprazoleA Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years OldPhase 2Terminated24Apr 13, 2026
BudesonideEfficacy of Nebulised Inhalational Steroids in Neonates With Meconium Aspiration SyndromePhase 3Completed60Apr 1, 2026
DazostinagA Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid TumorsPhase 2Completed · results248Mar 30, 2026
HGT-1110An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic LeukodystrophyPhase 2Completed24Feb 13, 2026
TAK-881A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency DiseasesPhase 3Completed · results65Jan 20, 2026
TAK-101Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free DietPhase 2Completed · results102Dec 9, 2025
TAK-771A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) ParticipantsPhase 3Completed · results15Oct 30, 2025
TAK-771A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)Phase 3Completed · results26Oct 28, 2025
TAK-279A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisPhase 3Completed · results18Oct 17, 2025
PioglitazonePioglitazone as an Adjunct to Cognitive-Behavioral Therapy for Cocaine Relapse PreventionPhase 2Completed61Sep 26, 2025
SoticlestatA Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut SyndromePhase 3Terminated · results352Sep 24, 2025
PonatinibPONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISISPhase 2Completed32Aug 31, 2025
GDX012A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid LeukemiaPhase 2Terminated · results16Aug 20, 2025
SoticlestatA Study of Soticlestat in Adults and Children With Rare EpilepsiesPhase 2Terminated · results156Jul 30, 2025
TAK-341A Study of TAK-341 in Treatment of Multiple System AtrophyPhase 2Completed · results158Jul 28, 2025
TAK-280First-in-Human Study of TAK-280 in Participants With Solid TumorsPhase 2Terminated · results69Jul 28, 2025
ENTYVIOA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)Phase 3Completed · results121Jul 1, 2025
TAK-186A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic CancerPhase 2Terminated · results95Jun 17, 2025
TRINTELLIXPostoperative Pain Management Following Laparoscopic CholecystectomyPhase 3Completed86Jun 7, 2025
ORZEYFULA Study of TAK-861 in People With Narcolepsy Type 1Phase 3Completed · results105Jun 4, 2025
ORZEYFULA Study of TAK-861 for the Treatment of Narcolepsy Type 1Phase 3Completed · results168Jun 3, 2025
TDVA Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in IndiaPhase 3Completed · results480May 5, 2025
ENTYVIOLong-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)Phase 2Completed · results59Apr 3, 2025
SoticlestatA Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to FenfluraminePhase 3Terminated · results1Aug 14, 2024
Lanthanum CarbonateLanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and NephrolithiasisPhase 3Completed54Aug 10, 2024
Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster DosePhase 3Completed · results365May 25, 2024